Redeye remains positive on the investment case in Xbrane Biopharma following its Q3 2022 report. Only a few weeks remain until the anticipated approval of Ximluci from the European Commission, and in turn, the Q1 2023 launch in Europe is nearing. We leave our comments.
LÄS MER